Jaguar Health Inc JAGX

$0.33 -0.03 (-7.42%)

Valuation

Market cap
739,000
Revenue TTM
$11,510,000
Net income TTM
$-53,430,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-464.21%
Debt to equity
0.35

Trading

Volume
471,100
Avg volume
3,032,112
Day's range
$0.31 – $0.38
Shares out
1,946,000
Stochastic %K
13%
Beta
-0.09
Analysts
—
Price target
$16.00

Price

Company profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription...

Show more

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 371 8300
Website
https://jaguar.health
Address
200 Pine Street, Suite 400, San Francisco, United States

Latest news

No headlines yet.

Stocktwits

Vextra Nov 19, 9:05 PM
Look at ticker FGI spiking now. crazy! If you want to be early for once look at FGI 🚀 FGI is just starting lets hope it pulls a OMH 2,000% type of run!! FGI on watch from $JAGX $HCTI $SOUN $BBAI )
0 replies
Bunster Nov 19, 6:25 PM
$JAGX ANOTHER ALL TIME LOW GIRLS AND BULLS....EV ERY LONG SHARE IN THE UNIVERSE EXCEPT THE DIVIDEND SHARES ARE UNDER WATER. GOOD JOB LISA .wHATS THAT,, THE 20TH 30TH 40TH OR 50TH ALL TIME LOW THIS YEAR???????????????????????
0 replies
Bunster Nov 19, 3:06 PM
$JAGX WHEN WILL LISA GO TO THE RS IN HER POCKET???????????
1 replies
Zackpedia Nov 18, 10:05 PM
$JAGX Down to .34, you could’ve…
0 replies
TimeForChangeNow Nov 18, 8:44 PM
$JAGX You all should start your own, but if anyone here lost on TNXP sign the petition, you do nothave to donate just skip that and create one to remove LISA https://stkt.co/BcoUDCbT
0 replies
LuckyIrish777 Nov 18, 7:01 PM
$JAGX This is probably Lisa.
0 replies
LuckyIrish777 Nov 18, 6:54 PM
$JAGX Alls you have to do is file a complaint with the FBI for fraud and you can get these people locked up. I don’t own any shares so I can’t do it but I feel bad for all the investors.
0 replies
Cheesyisi Nov 18, 6:50 PM
$JAGX all these paid pumpers by Lisa. How much longer till she sits behind bars for scamming investors?
0 replies